Bita Fakhri
Hematology · Palo Alto, CANPI 1568729424
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AbbVie at 37.8% of the total. Reporting peaked in 2023 at $65,133 and has fallen 66.7% since, to $21,686 in 2025. Among hematology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $1137.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Lilly USA, LLC$53K
- AstraZeneca$11K
- Genentech USA, Inc.$7K
- Eli Lilly$6K
- Pharmacyclics LLC, An Abbvie Company$5K
- plus $24K from 10 others
Across 762 payments — averaging $8847.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genmab A/s$2.3M
- Beigene, Ltd.$2.1M
- Eli Lilly$918K
- AbbVie$584K
- Beone Medicines Ltd.$526K
- Bristol Myers Squibb$196K
- plus $108K from 1 others
What the payments were for
- Consulting fees$90,03653%
- Speaking & faculty fees$66,72639%
- Travel & lodging$11,8727%
- Food & beverage$2,0591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $64,501 |
| Lilly USA, LLC | 37 | $52,821 |
| AstraZeneca | 16 | $11,049 |
| Genentech USA, Inc. | 9 | $7,262 |
| Eli Lilly | 3 | $6,031 |
| Pharmacyclics LLC, An Abbvie Company | 11 | $4,847 |
| CSL Behring | 5 | $4,500 |
| Beigene USA, Inc. | 2 | $3,500 |
| Johnson & Johnson | 3 | $3,288 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,973 |
| Amgen | 1 | $2,400 |
| Epizyme, Inc. | 1 | $1,813 |
| Seagen Inc. | 2 | $1,625 |
| Janssen Scientific Affairs, LLC | 1 | $1,515 |
| Secura Bio, Inc. | 1 | $1,320 |
| Adaptive Biotechnologies Corporation | 1 | $1,250 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$170,693 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JaypircaPirtobrutinib | 18 | $487,039 |
| BrukinsaZanubrutinib | 21 | $275,222 |
| ImbruvicaIbrutinib | 13 | $199,209 |
| CalquenceAcalabrutinib Maleate | 11 | $155,288 |
| Acyclovir | 16 | $230 |
| Levofloxacin | 17 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCJaypirca | $52,821 | $487,03918 claims |
| Beigene USA, Inc.Brukinsa | $3,500 | $275,22221 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $4,847 | $199,20913 claims |
| AstraZenecaCalquence | $11,049 | $155,28811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 178 hematology providers in California.
Other hematology in Palo Alto
- Steven CoutrePalo Alto$92K
- Jason GotlibPalo Alto$63K
- Everett MeyerStanford$2.1M
- Doris QuonLos Angeles$1.5M
- Amrita KrishnanDuarte$671K
- Ilene WeitzLos Angeles$631K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
- Alexey DanilovDuarte$407K
- Caroline PiatekLos Angeles$391K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.